Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
679 Leser
Artikel bewerten:
(2)

Grand Vision Media Holdings plc - Final Results

Finanznachrichten News

Grand Vision Media Holdings plc - Final Results

PR Newswire

London, 30 June 2022
FOR IMMEDIATE RELEASE


Grand Vision Media Holdings plc
( "GVMH" or the "Company")

Audited Final Results

Grand Vision Media Holdings plc announces its audited final results for the year ended 31 December 2021.

The CEO Report

Covid continues to have a significant adverse impact on the Group's performance for the year. OOH revenues were severely impacted by the closure of cinemas across China, and the closure of businesses in Hong Kong, together with the travel restrictions, adversely affected digital marketing revenues. Hong Kong and Shanghai both had their worst pandemic outbreak in the first half of 2022. There was a high degree of uncertainty throughout that period, with a resulting loss in overall business confidence. However, we do believe that the second half of the year will see improvements as the pandemic in the Greater China area is brought under control.

Summary of Trading Results

Total revenue for the year was HK$3,039K [2020: HK$5,827K], a decline of 48% compared to the prior year. This was as a direct result of the COVID restrictions and cinema closures in the region. Although the Group has been working on a number of initiatives to bolster revenues, the impact of the majority of these is only expected to come to fruition in Q3/2022 onwards.

The total comprehensive loss for the year was HK$6,184K [2020: HK$10,050K]. This was as a direct result of the reduction is revenues across the Group. The Group continued its cost savings through space consolidation and headcount reductions, and has taken advantage of Government fiscal support aimed at helping businesses through the pandemic.

The Group has 180 panels [2020: 180] in cinemas across China, and is evaluating other technologies to promote OOH advertising in the cinema space as well as other locations.

Cash in hand at the end of the year was HK$172K. The Group continues to manage its cash within its available resources.

Outlook

COVID-19 continues to have a significant adverse effect on the Group's performance in 2021. Much of Asia was under very strict lock down rules and international travel has been practically suspended. The lock down in Shanghai in early 2022 gave us further challenges for the first quarter of the current financial year. Cinemas in China are still operating at reduced capacity.

We continue to identify new opportunities and have begun some projects in relation to the brokering of commodities. We are also beginning to work on some projects assisting consumer brands to expand geographically.

However, we are hopeful for the resumption of cross border travel beginning in Q3 of the year and we expect a slow but steady return to normalcy in travel and trading for the remainder of the year.

These will shortly be available (along with the Company's 2021 Annual Report) to download on the Company's website at https://www.gvmh.co.uk/tag/financial-information/.

For more information contact:

Grand Vision Media Holdings plc
Jonathan Lo, Director
gvmh.co.uk/
Tel: +44 (0) 20 7866 2145
or info@gvmh.co.uk

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.